Ultimately, further investigation is required to determine the predictive capacity of various checkpoint inhibition molecules for response to immune checkpoint inhibition, and to date, no large clinical trials investigating TIM3 or LAG3 blockage have been reported for RCC. This evidence concerns the gene LAG3 and renal cell carcinoma.